Histology as a treatment effect modifier in advanced non‐small cell lung cancer: A systematic review of the evidence

Background and objective:  We conducted a systematic review of prospective, randomized, controlled trials (RCT) to examine whether histology had a treatment modifying effect (TME) on the efficacy outcomes of chemotherapeutic agents in patients with advanced (stage IIIB‐IV) non‐small cell lung cancer (NSCLC).

[1]  G. Scagliotti,et al.  The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. , 2009, The oncologist.

[2]  Kevin Carroll,et al.  Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) , 2005, The Lancet.

[3]  M H Cullen,et al.  The benefits of chemotherapy in patient subgroups with unresectable non-small-cell lung cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  V. Lorusso,et al.  Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  U. Gatzemeier,et al.  Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  W. Gregory,et al.  Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  T. Miller,et al.  Effect of alternating combination chemotherapy on survival of ambulatory patients with metastatic large-cell and adenocarcinoma of the lung. A Southwest Oncology Group Study. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Perry.  Textbook of Lung Cancer , 2001 .

[9]  G. Giaccone,et al.  Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J. Crowley,et al.  Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Edward S. Kim,et al.  Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial , 2008, The Lancet.

[12]  Jayne Tierney,et al.  Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Zinner,et al.  Treatment rationale and study design for a randomized trial of pemetrexed/carboplatin followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with advanced non-small-cell lung cancer of nonsquamous histology. , 2010, Clinical lung cancer.

[14]  Anna Spreafico,et al.  The Prognostic and Predictive Role of Histology in Advanced Non-small Cell Lung Cancer: A Literature Review , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  Miklos Pless,et al.  Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  F. Sperandi,et al.  Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer. , 2005, European journal of cancer.

[17]  G. Giaccone,et al.  Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy , 2009, Journal of Cancer Research and Clinical Oncology.

[18]  O. Brodin,et al.  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1995 .

[19]  Richard J Stephens,et al.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  H. Groen,et al.  Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  I. Vlachonikolis,et al.  Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial , 2001, The Lancet.

[22]  J. Lafitte,et al.  A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  S. Thongprasert,et al.  Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[24]  A. Iafrate,et al.  Genetically informed lung cancer medicine , 2011, The Journal of pathology.

[25]  Kenji Eguchi,et al.  Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  F. Guidi,et al.  A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  K. Krejcy,et al.  Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study , 2009, The Lancet.

[28]  Y. Nishiwaki,et al.  Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study. , 2008, The Lancet. Oncology.

[29]  A. Ardizzoni,et al.  Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. , 2007, Journal of the National Cancer Institute.

[30]  Robert Pirker,et al.  Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial , 2009, The Lancet.

[31]  A. Dowlati,et al.  Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  S. Kaasa,et al.  Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Johan Vansteenkiste,et al.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Renato Martins,et al.  Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.

[35]  V. Georgoulias,et al.  Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial. , 2001, Lung cancer.

[36]  C. Gridelli,et al.  Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Roy S Herbst,et al.  Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Xin Li,et al.  TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  T. Fleming,et al.  A controlled evaluation of combined 5-fluorouracil, doxorubicin, and mitomycin C (FAM) for the treatment of advanced non-small-cell lung cancer. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  P. Zimmerman,et al.  Approval Summary for Erlotinib for Treatment of Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer after Failure of at Least One Prior Chemotherapy Regimen , 2005, Clinical Cancer Research.

[41]  C. Obasaju,et al.  Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV , 2009, Clinical lung cancer.

[42]  S. Barni,et al.  Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  B. Freidlin,et al.  Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.